---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-256325"
form_type: "8-K"
ticker: "OPK"
cik: "0000944809"
company_name: "OPKO HEALTH, INC."
filed_at: "2025-10-29T23:59:59+00:00"
generated_at: "2026-05-17T01:50:00.489860+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# OPKO Q3 net income $21.6M; Regeneron collaboration with $1B+ potential; sells BioReference oncology to Labcorp for $225M

## Summary
- Q3 consolidated revenues $151.7M, down 12.6% YoY; operating income $48.1M vs $14.2M; diluted EPS $0.03 flat.
- Entered multi-program Regeneron collaboration for multispecific antibodies; upfront plus milestones >$200M per program, total potential >$1B.
- Completed sale of BioReference oncology assets to Labcorp for $225M ($192.5M cash + $32.5M earnout); net gain of $101.6M recorded.
- Pharmaceuticals revenue $37.7M (Rayaldee $7.5M, up 29%); diagnostics revenue $95.2M, down due to prior-year asset sales.
- Cash, cash equivalents and restricted cash $428.9M at Sep 30, 2025; $73.8M used in share repurchase program.

## SEC filing metadata
- accession: 0001193125-25-256325
- form_type: 8-K
- ticker: OPK
- cik: 0000944809
- company_name: OPKO HEALTH, INC.
- filed_at: 2025-10-29T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/944809/000119312525256325/0001193125-25-256325-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/944809/000119312525256325/opk-20251029.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-256325
- JSON: https://secwatch.observer/filing/0001193125-25-256325.json
- Plain text: https://secwatch.observer/filing/0001193125-25-256325.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.